 Zacks Investment Research cut shares of BIOLASE NASDAQ:BIOL from a buy rating to a sell rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, Biolaw Technology, Inc. is the worlds leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that ... 